(Total Views: 684)
Posted On: 08/13/2020 6:51:23 PM
Post# of 154977
Re: chazzledazzle #49360
Lots more tears and conspiracy theories on here than normal, I'll chalk that up to the 4.00 close, and let people grieve.
During a recent call, NP asked MM about uplisting by the third week of August. MM said and I quote "er uh yeah, it's possible" (I like MM this isn't poking fun at him). Uplisting by the 3rd week of August is likely another NP over promise. I def don't think uplisting in general is off the table. Still some time to prove me wrong about it being an over promise btw.
Like others I thought COVID was a waste of time and resources, in my opinion to date management has proven me wrong. I am at peace with the fact that other therapies maybe vaccines beats us to market. I think in the SC population we have a good chance of being better than most (maybe all) therapeutics. As for the mild to moderate population, there is less competition, and a large global market. Globally there will be a shortage of effective therapies at least for the first 12 months. We will have a safe and effective product to sell. I think the chance that we make 100-XXX million in the first 12 months somewhere in the world after approval is high.
All that being said I'm really here for Cancer, HIV, NASH, and maybe in 6 months I'll say MS and Alzheimers. COVID could provide us with some much needed cash in the short term, and am betting that it does.
During a recent call, NP asked MM about uplisting by the third week of August. MM said and I quote "er uh yeah, it's possible" (I like MM this isn't poking fun at him). Uplisting by the 3rd week of August is likely another NP over promise. I def don't think uplisting in general is off the table. Still some time to prove me wrong about it being an over promise btw.
Like others I thought COVID was a waste of time and resources, in my opinion to date management has proven me wrong. I am at peace with the fact that other therapies maybe vaccines beats us to market. I think in the SC population we have a good chance of being better than most (maybe all) therapeutics. As for the mild to moderate population, there is less competition, and a large global market. Globally there will be a shortage of effective therapies at least for the first 12 months. We will have a safe and effective product to sell. I think the chance that we make 100-XXX million in the first 12 months somewhere in the world after approval is high.
All that being said I'm really here for Cancer, HIV, NASH, and maybe in 6 months I'll say MS and Alzheimers. COVID could provide us with some much needed cash in the short term, and am betting that it does.
(3)
(0)
